Kinnate Biopharma Stock Return On Asset
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate Biopharma fundamentals help investors to digest information that contributes to Kinnate Biopharma's financial success or failures. It also enables traders to predict the movement of Kinnate Stock. The fundamental analysis module provides a way to measure Kinnate Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kinnate Biopharma stock.
Kinnate |
Kinnate Biopharma Company Return On Asset Analysis
Kinnate Biopharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kinnate Biopharma Return On Asset | -0.34 |
Most of Kinnate Biopharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kinnate Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Kinnate Biopharma has a Return On Asset of -0.3363. This is 96.16% lower than that of the Biotechnology sector and 98.57% lower than that of the Health Care industry. The return on asset for all United States stocks is 140.21% higher than that of the company.
Kinnate Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kinnate Biopharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics of similar companies.Kinnate Biopharma is currently under evaluation in return on asset category among its peers.
Kinnate Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) | |||
| Cash And Equivalents | 262.42 M | |||
| Cash Per Share | 5.94 X | |||
| Total Debt | 3.17 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 23.30 X | |||
| Book Value Per Share | 3.66 X | |||
| Cash Flow From Operations | (100.04 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (2.78) X | |||
| Target Price | 2.36 | |||
| Number Of Employees | 84 | |||
| Beta | 1.34 | |||
| Market Capitalization | 124.99 M | |||
| Total Asset | 173.6 M | |||
| Retained Earnings | (372.01 M) | |||
| Working Capital | 146.18 M | |||
| Z Score | 19.38 | |||
| Net Asset | 173.6 M |
About Kinnate Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |